BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5% PROVIDES A RAPID AND SUSTAINED REDUCTION IN OCULAR ITCH FOR SEVERELY ALLERGIC SUBJECTS FOLLOWING EXPOSURE TO RAGWEED OR GRASS POLLENS USING THE CONJUNCTIVAL ALLERGEN CHALLENGE (CAC) MODEL OF ALLERGIC CONJUNCTIVITIS

被引：0

作者：

Munoz, M. ^{[1
]}

Williams, J. I. ^{[1
]}

Gow, J. A. ^{[1
]}

Schooley, G. L. ^{[1
]}

McNamara, T. R. ^{[1
]}

机构：

[1] Bepotastine Besilate Ophthalm Solut Study, Irvine, CA USA

来源：

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2011年 / 107卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：A113 / A113

页数：1

共 18 条

[1] Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Tearing 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis
Williams, J. I.
McLaurin, E. B.
Kurata, F. K.
Abelson, M. B.
Gow, J. A.
McNamara, T. R.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB257 - AB257
[2] Bepotastine Besilate Ophthalmic Solution 1.5% Produces Strong Clinical Benefit for Ocular Itching Immediately Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis
Clark, J. C.
Williams, J. I.
Gomes, P. J.
Abelson, M. B.
Gow, J. A.
McNamara, T. R.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB256 - AB256
[3] TREATMENT OF OCULAR ITCHING WITH BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5% FOR SUBJECTS WITH MORE SEVERE ITCHING RESPONSE IN A CONJUNCTIVAL ALLERGEN CHALLENGE (CAC) CLINICAL MODEL OF ALLERGIC CONJUNCTIVITIS
Kennedy, K. S.
Williams, J. I.
Gow, J. A.
Abelson, M. B.
McNamara, T. R.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2009, 103 (05) : A129 - A129
[4] Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Nonocular Composite Symptom (NOCS) Scores 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis
Gow, J. A.
Macejko, T. T.
Bergmann, M. T.
Meier, E.
Abelson, M. B.
Williams, J. I.
McNamara, T. R.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB255 - AB255
[5] Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Ocular Itching in a Clinical Model of Allergic Conjunctivitis
Torkildsen, G. L.
Gomes, P. J.
Williams, J. I.
Gow, J. A.
McNamara, T. R.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S57 - S57
[6] BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5% REDUCES NASAL CONGESTION WITH RAPID ONSET IN A CLINICAL MODEL OF ALLERGIC CONJUNCTIVITIS
Torkildsen, G. L.
Williams, J. I.
Gow, J. A.
Gomes, P. J.
McNamara, T. R.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2009, 103 (05) : A130 - A130
[7] Rhinorrhea Reduction Using BepreveTm Ophthalmic Solution 1.5% in a Clinical Model of Allergic Conjunctivitis: An Analysis of Pooled Data From Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials
Gow, J. A.
Williams, J. I.
Gomes, P. J.
Abelson, M. B.
McNamara, T. R.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
[8] Treatment of Chronic Allergic Conjunctivitis with Sustained Release Dexamethasone Using a Modified Conjunctival Allergen Challenge (Ora-CAC®) Model
Mulani, Deepa
McLaurin, Eugene B.
Repke, Carolyn
Sato, Michelle
Gomes, Paul J.
Ankerud, Eric
Bassett, Michael
Blizzard, Charles D.
Driscoll, Arthur
Sawhney, Amar
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
[9] Evaluating Sustained Release Dexamethasone for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge (Ora-CAC®) Model
Bassett, Michael
Mulani, Deepa
Blizzard, Charles D.
Driscoll, Arthur
Sawhney, Amar
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
[10] Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model
Netland, PA
Leahy, C
Krenzer, KL
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2000, 130 (06) : 717 - 723

← 1 2 →